Dynavax Technologies Corporation (NASDAQ:DVAX)‘s stock had its “outperform” rating restated by investment analysts at Royal Bank Of Canada in a report released on Monday. They presently have a $28.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $26.00. Royal Bank Of Canada’s price objective would indicate a potential upside of 36.59% from the company’s previous close.

DVAX has been the subject of a number of other reports. Zacks Investment Research cut shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. ValuEngine cut shares of Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. William Blair restated an “outperform” rating on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. Cowen and Company restated an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Thursday, August 10th. Finally, Cantor Fitzgerald began coverage on shares of Dynavax Technologies Corporation in a report on Friday, September 15th. They set an “overweight” rating and a $24.00 price target for the company. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $25.00.

Dynavax Technologies Corporation (NASDAQ DVAX) opened at 20.50 on Monday. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $21.85. The firm’s market cap is $1.12 billion. The company has a 50 day moving average price of $17.84 and a 200 day moving average price of $9.78.

Dynavax Technologies Corporation (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.15 million. During the same period in the prior year, the company earned ($0.75) earnings per share. On average, equities research analysts forecast that Dynavax Technologies Corporation will post ($1.60) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Dynavax Technologies Corporation (DVAX) Given Outperform Rating at Royal Bank Of Canada” was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/25/dynavax-technologies-corporation-dvax-rating-reiterated-by-royal-bank-of-canada-2.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its stake in shares of Dynavax Technologies Corporation by 2.3% in the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 456 shares during the period. Nationwide Fund Advisors lifted its stake in shares of Dynavax Technologies Corporation by 2.5% in the second quarter. Nationwide Fund Advisors now owns 28,359 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 692 shares during the period. Parametric Portfolio Associates LLC lifted its stake in shares of Dynavax Technologies Corporation by 3.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 939 shares during the period. American International Group Inc. lifted its stake in shares of Dynavax Technologies Corporation by 7.1% in the first quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 1,584 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Dynavax Technologies Corporation by 16.5% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 1,700 shares during the period. Institutional investors and hedge funds own 60.20% of the company’s stock.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.